This site is intended for healthcare professionals
News

Data from phase III studies,GEMSTONE-301 and GEMSTONE-302, of sugemalimab for NSCLC were published in The Lancet Oncology.- EQRx Inc., and CStone Pharmaceuticals.

Read time: 1 mins
Published:20th Jan 2022
EQRx, Inc. a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, announced that data from its partner CStone Pharmaceuticals’ two pivotal Phase III studies of the anti-PD-L1 monoclonal antibody sugemalimab for the treatment of non-small cell lung cancer (NSCLC), GEMSTONE-301 and GEMSTONE-302, were published in The Lancet Oncology.

See-" Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase III trial"-Prof Qing Zhou, MD, Prof Ming Chen, MD ,Prof Ou Jiang, MD, et al. Published:January 14, 2022DOI:https://doi.org/10.1016/S1470-2045(21)00630-6.The Lancet Oncology.

See-"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase III clinical trial".Prof Caicun Zhou, MD ,Prof Ziping Wang, MD,Prof Yuping Sun, MD,et al. Published: 14 January ,m2022DOI:https://doi.org/10.1016/S1470-2045(21)00650-1. The Lancet Oncology.

Condition: Non Small Cell Lung Cancer
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.